Amivantamab is a humanized EGFR-cMET BsAb that has shown a managed safety profile and broad-spectrum anti-tumor efficacy in patients with EGFR exon 20 insertion, EGFR C797S mutation, MET amplification, or resistance to third-generation EGFR TKI Osimertinib [40]. Here, MET is linked to neoplasm.